COLGATE-PALMOLIVE CO (CL)       77.55  +0.34 (+0.44%)

77.55  +0.34 (+0.44%)

US1941621039 - Common Stock - After market: 77.55 0 (0%)


Fundamental Rating

5

Taking everything into account, CL scores 5 out of 10 in our fundamental rating. CL was compared to 12 industry peers in the Household Products industry. CL has a great profitability rating, but there are some minor concerns on its financial health. CL is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

7

CL's Return On Assets of 11.84% is amongst the best returns of the industry. CL outperforms 81% of its industry peers. The industry average Return On Assets is 6.58%.
CL's Return On Equity of 309.97% is amongst the best returns of the industry. CL outperforms 90% of its industry peers. The industry average return on equity is 19.98%.

CL's Profit Margin of 10.87% is amongst the best of the industry. CL does better than the industry average Profit Margin of 6.82%.
CL has a Piotroski-F score of 5.00. This indicates an average health and profitability for CL.
VS Industry

ROA (11.84%) VS Industry: 81% outperformed.

-5.06
15.50

ROE (309.97%) VS Industry: 90% outperformed.

3.76
408.24

Profit Margin (10.87%) VS Industry: 72% outperformed.

-7.59
18.11

Valuation

Valuation Rating

1

CL's Price/Earning Ratio is in line with the industry average which is at 26.04.
The Forward Price/Earnings Ratio of 23.19 indicates a rather expensive current valuation of CL.
When comparing the Enterprise Value to EBITDA ratio of CL to the average industry ratio of 16.95, CL is valued in line with its industry peers.
With a Price/Earnings Ratio of 25.94, CL can be considered very expensive at the moment.

The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
When comparing the current price to the book value of CL, we can conclude it is valued rather expensively. It is trading at 104.13 times its book value.
When comparing the price book ratio of CL to the average industry price book ratio of 8.08, CL is valued more expensive than its industry peers. 91% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (25.94) VS Industry: 54% outperformed.

43.31
11.10

Price/Book (104.13) VS Industry: 9% outperformed.

105.57
1.50

Enterprise Value/ EBITDA (16.95) VS Industry: 45% outperformed.

29.41
9.22

Growth

Growth Rating

4

When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
CL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.97%.
CL shows a small growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 2.63% yearly.
Based on estimates for the next 5 years, CL will show a small growth in Earnings Per Share. The EPS will grow by 4.87% on average per year.

The Revenue has been growing slightly by 2.30% in the past year.
The Revenue has been growing slightly by 2.77% on average over the past 5 years.
The Revenue is expected to grow by 1.58% on average over the next 5 years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS2.63% 2.52% -5.97% -3.2% 2.22% 3.99% 4.87%
Revenue2.77% 3.87% 2.3% 2.66% 2.48% 3.01% 1.58%

Health

Health Rating

5

An Altman-Z score of 6.51 indicates that CL is not in any danger for bankruptcy at the moment.
The Altman-Z score of CL is much better than the industry average of 3.74. CL has a better rating than 90% of its industry peers.
A Current Ratio of 1.17 indicates that CL should not have too much problems paying its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 1.17.

CL has a Piotroski-F score of 5.00. This indicates an average health and profitability for CL.
Compared to an average industry Current Ratio of 2.25, CL is worse placed to pay its short term obligations than its industry peers.
A Quick Ratio of 0.71 indicates that CL may have some problems paying its short term obligations.
Compared to an average industry Debt to Equity Ratio of 1.15, CL is requires more financing than its industry peers. 82% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (13.21) VS Industry: 18% outperformed.

26.79
0.21

Quick Ratio (0.71) VS Industry: 45% outperformed.

0.41
2.07

Current Ratio (1.17) VS Industry: 36% outperformed.

0.62
3.34

Altman-Z (6.51) VS Industry: 90% outperformed.

1.46
9.45

Dividend

Dividend Rating

3

CL has been paying a dividend for at least 10 years, so it has a reliable track record.
CL has a Yearly Dividend Yield of 2.45%.
CL's Dividend Yield is comparable with the S&P500 average which is at 2.43.
The dividend of CL has a limited annual growth rate of 2.55%.

Compared to an average industry Dividend Yield of 3.16, CL is paying slightly less dividend.
CL's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
88.28% of the earnings are spent on dividend by CL. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (2.45%) VS Industry: 22% outperformed.

1.33
3.63
CL Daily chart

COLGATE-PALMOLIVE CO77.55

NYSE:CL (12/7/2022, 7:04:00 PM)+0.34 (+0.44%)

After market: 77.55 0 (0%)

Chartmill FA Rating
GICS Sector Consumer Staples
GICS IndustryGroup Household & Personal Products
GICS Industry Household Products
Earnings (Last) 10-28 2022-10-28/bmo Earnings (Next) 01-27 2023-01-27
Ins Owners 0.07% Inst Owners 78.68%
Market Cap 64.77B Analysts 69.7
Valuation
PE 25.94 Fwd PE 23.19
PEG (NY) N/A PEG (5Y) 9.85
P/S 3.65 P/B 104.13
EV/EBITDA 16.95
Dividend
Dividend Yield 2.45% Dividend Growth 2.55%
DP 88.28% Ex-Date 10-20 2022-10-20 (0.47)
Growth
EPS 1Y -5.97% EPS 3Y 2.52%
EPS 5Y 2.63% EPS growth Q2Q -8.64%
EPS Next Y -3.2% EPS Next 2Y 2.22%
EPS Next 3Y 3.99% EPS Next 5Y 4.87%
Revenue growth 1Y 2.3% Revenue growth 3Y 3.87%
Revenue growth 5Y 2.77% Revenue growth Q2Q 0.93%
Revenue Next Year 2.66% Revenue Next 2Y 2.48%
Revenue Next 3Y 3.01% Revenue Next 5Y 1.58%
Health
Current Ratio 1.17 Quick Ratio 0.71
Altman-Z 6.51 F-Score 5
Debt/Equity 13.21 WACC 7.52%
ROIC/WACC 7.74
Profitability
ROA 11.84% ROE 309.97%
ROICexgc 58.19% ROIC 24.18%
PM 10.87% OM 20.89%
Asset Turnover 1.09

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA